Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723073 · ClinicalTrials.gov registry record
Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 323
- Enrollment target
NCT00723073 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 323 participants.
The verdict
NCT00723073 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 323 participants
- Enrollment target
Study Summary
Invasive fungal infections are an important cause of morbidity and mortality in patients with neutropenia who are receiving chemotherapy for cancer. Early diagnosis of these infections is difficult and fever may be the only sign. A delay in treatment while a diagnosis is pursued may lead to increased morbidity and mortality. There are now several echinocandins available with similar in vitro spectrum of activity. Caspofungin is the only echinocandin Food and Drug Administration (FDA) approved for empiric antifungal therapy in febrile neutropenia. Although all echinocandin antifungal agents have similar spectrum of activity, there are limited data on the use of micafungin in patients with persistent fever and neutropenia (FN). In November 2006 the Pharmacy and Therapeutics Committee at Brigham \& Women's Hospital / Dana Farber Cancer Institute (BWH/DFCI) switched from caspofungin to micafungin as our formulary echinocandin. Given the limited clinical data on the use of micafungin as empiric antifungal therapy in patients with FN, we sought to evaluate the safety and effectiveness of micafungin, compared with caspofungin, for this indication using a sequential cohort analysis of patients treated before and after the formulary change at Brigham and Women's Hospital.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723073
The ClinicalTrials.gov registry entry for NCT00723073 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00723073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00723073 about?
NCT00723073 is a clinical study titled "Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia". Invasive fungal infections are an important cause of morbidity and mortality in patients with neutropenia who are receiving chemotherapy for cancer. Early diagnosis of these infections is difficult and fever may be the only sign. A delay in treatment while a diagnosis is pursued may lead to increase...
What is the current status of trial NCT00723073?
This trial is currently completed. The enrollment target is 323 participants. The study started on 2008-01. Estimated completion is 2008-05.
Who is sponsoring clinical trial NCT00723073?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.